Who is sponsoring NCT04617899?

NCT04617899 is sponsored by CardioNavi MedTech (Wuhan) Co., Ltd..

What drugs are being tested in NCT04617899?

Interventions in NCT04617899: Intravascular imaging.

What condition does NCT04617899 study?

NCT04617899 studies Coronary Artery Disease.

Is NCT04617899 still recruiting?

NCT04617899 is currently status unknown. Last updated 1 June 2021.

Last reviewed 2021-06-01 · How we verify

NCT04617899: SUPERIOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The StUdy to Evaluate the Performance and safEty of the Novasight HybRid System Using Objective PeRformance Criteria

Status unknown NA Last updated 1 June 2021

What this trial tests

NA trial testing Intravascular imaging in Coronary Artery Disease in 120 participants. Status unknown.

Timeline

17 March 2021

Primary endpoint
30 November 2021

31 December 2021

Quick facts

Lead sponsor	CardioNavi MedTech (Wuhan) Co., Ltd.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	120
Start date	17 March 2021
Primary completion	30 November 2021
Estimated completion	31 December 2021
Sites	4 locations across China

Drugs / interventions tested

Intravascular imaging

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

CardioNavi MedTech (Wuhan) Co., Ltd.

Who can join

Adults 18 to 85, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, multicenter, single-arm study aims to evaluate the safety, operability and practicability of the novel hybrid intravascular imaging system/catheter during the percutaneous transluminal coronary intervention.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Multicenter Feasibility and Safety Study of a Novel Hybrid IVUS-OCT Imaging System.
Jin Q, Fu Z, Wang Y, Zeng Y, et al · · 2025 · cited 3× · PMID 40049934 · DOI 10.1016/j.jacasi.2025.01.009

Verify or expand the search:

Other trials of Intravascular imaging

Trials testing the same drug.

NCT05369182 — Multicenter Registry of Coronary Flow-Derived Indexes for Coronary Microvascular Disease (Multicenter FLOW-CMD Registry) · active not recruiting

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04617899 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CardioNavi MedTech (Wuhan) Co., Ltd.
Last refreshed: 1 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04617899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing